Aggrastat (tirofiban) / Correvio, Medicure - LARVOL DELTA

COMPARISON OF TIROFIBAN VERSUS CANGRELOR AS A TEMPORARY ANTIPLATELET BRIDGING AGENT FOR CORONARY STENT PROTECTION (ACC 2026) - "Abstract is embargoed at this time."

ATTRACTION: Tirofiban After Successful MT Recanalization in AIS (clinicaltrials.gov) - P2/3 | N=1380 | Completed | Sponsor: Xiang Luo | Recruiting ➔ Completed

Trial completion • Cardiovascular • Ischemic stroke

Development and validation of a clinical model for predicting 90-day outcomes after endovascular therapy with adjunctive tirofiban in acute ischemic stroke. (PubMed, Front Neurol) - "We developed and validated a pragmatic prediction model incorporating readily available clinical and procedural variables to estimate the risk of 90-day poor outcome in AIS-LVO patients treated with EVT and tirofiban. This tool may assist clinicians in individualized outcome prediction and inform adjunctive antithrombotic strategies in neurovascular care."

Journal • Cardiovascular • Cerebral Hemorrhage • CNS Disorders • Hematological Disorders • Infectious Disease • Ischemic stroke • Pneumonia • Respiratory Diseases

Efficacy and safety of intra-arterial tirofiban in acute ischemic stroke without large-vessel occlusion. (PubMed, Neuro Endocrinol Lett) - "Intra-arterial tirofiban administration benefits AIS patients without large- or medium-vessel occlusions, improving neurological function, reducing disability, and enhancing functional independence."

Journal • Cardiovascular • Ischemic stroke

Impact of Prestroke Antiplatelet Therapy on the Efficacy of Intravenous Tirofiban at Preventing Early Neurological Deterioration: A Prespecified Subgroup Analysis of the TREND Trial. (PubMed, Am J Cardiovasc Drugs) - P2/3 | "Intravenous tirofiban significantly reduced the risk of END compared with aspirin in patients with AIS who were not on prestroke APT. Although this benefit was attenuated in pretreated patients, tirofiban might maintain a consistent efficacy and safety profile irrespective of prior antiplatelet use."

Journal • Cardiovascular • Ischemic stroke

Development and validation of an interpretable machine learning model to predict malignant cerebral edema after endovascular treatment in acute anterior circulation large vessel occlusion stroke. (PubMed, Front Neurol) - "Additional 162 patients from the One Pass Tirofiban In Management of Ischemic Stroke Thrombectomy In China (OPTIMISTIC) trial were included as an external validation set...The random forest model performed best, achieving an AUC of 0.901 (95% CI: 0.858-0.943) in the training set, 0.849 (95% CI: 0.700-0.970) in the internal validation set, and 0.724 (95% CI: 0.606-0.841) in the external validation set. This study developed and externally validated an interpretable machine learning model to predict the risk of MCE in patients with acute anterior circulation LVO stroke following EVT."

Journal • Cardiovascular • Ischemic stroke

Thrombolysis with Adjunctive Tirofiban in Acute Non-cardioembolic Posterior Circulation Ischemic Stroke: A Propensity Score-Matched Analysis. (PubMed, Neurol Ther) - "In patients with acute non-cardioembolic posterior circulation ischemic stroke treated within 24 h of onset, adjunctive tirofiban following standard intravenous thrombolysis was associated with significantly improved 90-day functional outcomes without a notable increase in major bleeding risk, particularly in patients with lower baseline NIHSS scores."

Journal • Cardiovascular • Cerebral Hemorrhage • CNS Disorders • Hematological Disorders • Ischemic stroke

Tirofiban-induced lingual edema and thrombocytopenia during management of ischemic stroke: a case report. (PubMed, Neurol Sci) - No abstract available

Journal • Cardiovascular • Hematological Disorders • Ischemic stroke • Thrombocytopenia

STRATEGY: Study on Tirofiban With Aspirin in the Treatment of Acute Penetrating Artery Territory Infarction (clinicaltrials.gov) - P4 | N=970 | Completed | Sponsor: Beijing Tiantan Hospital | Recruiting ➔ Completed | Trial completion date: Sep 2024 ➔ Sep 2025 | Trial primary completion date: Jun 2024 ➔ Feb 2025

Trial completion • Trial completion date • Trial primary completion date

RESCUE-AS: Intravenous Tirofiban After Bridging Therapy for Acute Stroke With Atherosclerotic Large Artery Occlusion (clinicaltrials.gov) - P3 | N=564 | Not yet recruiting | Sponsor: Beijing Tiantan Hospital

New P3 trial • Atherosclerosis • Cardiovascular • Ischemic stroke

Safety and efficacy of adjunctive Tirofiban and Eptifibatide in acute ischemic stroke: a systematic review and meta-analysis. (PubMed, J Stroke Cerebrovasc Dis) - "Our meta-analysis suggests that while adjunctive tirofiban or eptifibatide with IVT do not yield benefits in terms of reducing mortality or improving functional independence at 90 days in AIS, emerging evidence from RCTs indicates that tirofiban may offer functional benefits, though this remains uncertain. Importantly, adjunctive therapy did not demonstrate a significant increase in bleeding risk in the analyzed studies. . These findings support the need for further large-scale, high-quality randomized controlled trials to explain the role of tirofiban in the management of AIS."

Journal • Retrospective data • Cardiovascular • Cerebral Hemorrhage • CNS Disorders • Hematological Disorders • Ischemic stroke • Vascular Neurology

High-throughput combinatorial screening of antiplatelet drugs for personalized medicine. (PubMed, Microsyst Nanoeng) - "We demonstrate that the C-chip can effectively identify the optimal combinations of three clinically relevant antiplatelet drugs: Aspirin, Tirofiban, and Ticagrelor. We further applied this platform to identify optimal drug combinations for five healthy volunteers, revealing marked inter-individual variability in antiplatelet drug responses."

Journal • Cardiovascular • Myocardial Infarction

Adjunct tirofiban after intravenous thrombolysis in acute ischemic stroke: a GRADE-guided meta-analysis of randomized trials with trial sequential analysis. (PubMed, J Thromb Thrombolysis) - "Our analysis assessed the efficacy and safety of adjunct tirofiban after IVT versus IVT alone (alteplase or Tenecteplase) in patients with AIS. For safety, no statistically significant differences were observed in any ICH, asymptomatic ICH, systemic bleeding, or 90-day mortality; however, the estimate for sICH was very imprecise and does not exclude a clinically important increase. These results are exploratory and warrant confirmation in larger, multinational RCTs before informing practice."

Journal • Retrospective data • Review • Cardiovascular • Cerebral Hemorrhage • CNS Disorders • Hematological Disorders • Ischemic stroke

Efficacy and safety of intravenous tirofiban pre-operatively as an adjunct to endovascular thrombectomy in ischemic stroke: a grade-assessed systematic review and Meta-Analysis. (PubMed, J Thromb Thrombolysis) - "Heterogeneity was moderate to low, and findings were consistent across study types. Future studies should explore optimal patient selection, dosing strategies, and timing to identify potential subgroups that may benefit from pre-EVT tirofiban."

Journal • Retrospective data • Review • Cardiovascular • Cerebral Hemorrhage • CNS Disorders • Hematological Disorders • Ischemic stroke

Real-world safety of tirofiban: a disproportionality analysis using data from FAERS and WHO-VigiAccess. (PubMed, Front Pharmacol) - "Management strategies, such as dose adjustment, temporary discontinuation, or supportive treatment including platelet transfusion, may help mitigate severe complications. These findings provide real-world evidence to guide safer tirofiban use, although further studies are required to confirm causality."

Journal • Real-world evidence • Cardiovascular • Coronary Artery Disease • Geriatric Disorders • Heart Failure • Hematological Disorders • Thrombocytopenia • Thrombosis

Tirofiban for Preventing Early Neurological Deterioration in Acute Ischemic Stroke Within 48 Hours of Onset: Evidence From a Dual-Method Analysis Using Propensity Score Matching and Multivariable Regression. (PubMed, CNS Neurosci Ther) - P4 | "For AIS patients without LVO, early intravenous tirofiban within 48 h of onset effectively reduced the risk of END and promoted early or long-term neurological improvement without increasing bleeding risk, suggesting a potential therapeutic benefit in an extended time window, especially for the BAD subtype."

Clinical • Journal • Cardiovascular • Cerebral Hemorrhage • CNS Disorders • Hematological Disorders • Ischemic stroke

ADJUVANT: Intravenous Tirofiban Versus Alteplase Before Mechanical Thrombectomy in Stroke (clinicaltrials.gov) - P2/3 | N=800 | Recruiting | Sponsor: Xinqiao Hospital of Chongqing | Trial completion date: Jun 2027 ➔ Jul 2026 | Trial primary completion date: Mar 2027 ➔ Feb 2026

Trial completion date • Trial primary completion date • Cardiovascular • Ischemic stroke

PlateChek: A Surface-functionalized Dielectric Microsensor for Specific Detection of Platelet-related Hemostatic Impairment in Whole Blood. (PubMed, J Thromb Haemost) - "PlateChek is a novel whole blood-based coagulometer with translational potential that directly correlates both platelet count and function defects to hemostatic impairment."

Journal • Hematological Disorders • Thrombocytopenia

ATTIS: Early Administration of Tirofiban in Patients Treated With Tenecteplase for Acute Ischemic Stroke (clinicaltrials.gov) - P3 | N=348 | Recruiting | Sponsor: Second Affiliated Hospital of Guangxi Medical University | Phase classification: P4 ➔ P3 | N=600 ➔ 348 | Trial completion date: Dec 2025 ➔ Mar 2026 | Trial primary completion date: Mar 2025 ➔ Dec 2025 | Not yet recruiting ➔ Recruiting

Enrollment change • Enrollment open • Phase classification • Trial completion date • Trial primary completion date • Cardiovascular • Ischemic stroke

Intravenous Thrombolysis Combined With Tirofiban in Acute Ischemic Stroke (clinicaltrials.gov) - P4 | N=976 | Recruiting | Sponsor: Beijing Anzhen Hospital | Not yet recruiting ➔ Recruiting

Enrollment open • Cardiovascular • Ischemic stroke

Intravenous Thrombolysis Combined With Tirofiban in Acute Ischemic Stroke (clinicaltrials.gov) - P4 | N=976 | Not yet recruiting | Sponsor: Beijing Anzhen Hospital

New P4 trial • Cardiovascular • Ischemic stroke

Endovascular Parent Artery Reconstruction for Ruptured Intracranial Blister Aneurysms: Demonstrating Safety and Efficacy After Early Flow Diversion. (PubMed, Cureus) - "The concept of endoluminal parent artery reconstruction using a flow diverter device is promising for the treatment of ruptured intracranial blister aneurysms. Early flow diversion combined with strong clinical data from this series shows that a DAPT regimen is safe and necessary in this emergency situation, successfully reducing thromboembolic problems without immediately increasing the risk of hemorrhagic sequelae."

Journal • Cardiovascular • Hematological Disorders • Subarachnoid Hemorrhage • Thrombosis

Efficacy and safety of adjunctive tirofiban administration in anterior large vessel occlusion due to large artery atherosclerosis: an individual patient data pooled analysis of two randomized clinical trials. (PubMed, Int J Surg) - "In patients with anterior circulation LVO secondary to LAA undergoing EVT, adjunctive tirofiban, whether administered IV or via a combined IA + IV approach, was associated with superior 90-day functional outcomes and enhanced recanalization efficacy, without an increased risks of sICH or mortality."

Clinical • Journal • Retrospective data • Atherosclerosis • Cardiovascular • Cerebral Hemorrhage • CNS Disorders • Hematological Disorders • Ischemic stroke

A rare case of fulminant myocarditis complicated with thrombotic aorta occlusion and multiple thrombosis: a case report. (PubMed, Front Med) - "The patient was provided with a comprehensive treatment involving anticoagulants (enoxaparin, tirofiban), immunomodulatory agents (methylprednisolone, immunoglobulin), antiviral agent (oseltamivir), and intra-aortic thrombus aspiration via the right femoral artery. After undergoing these treatments for 19 days, her cardiac function returned to normal and subsequent CT images showed a dramatic reduction in aortic thrombosis. Moreover, full recovery of blood flow and movement function of the bilateral lower extremities was observed."

Journal • Cardiovascular • Hematological Disorders • Immunology • Infectious Disease • Inflammation • Influenza • Myositis • Respiratory Diseases • Thrombosis

Safety and efficacy of sequential intra-arterial and intravenous administration of tirofiban during the periprocedural period of stenting in perforator-rich intracranial arteries. (PubMed, J Neurointerv Surg) - "Periprocedural intra-arterial with intravenous tirofiban reduced early AST, without increasing the risk of hemorrhage, for stenting of perforator-rich intracranial arteries."

Journal • Atherosclerosis • Cardiovascular • Cerebral Hemorrhage • CNS Disorders • Diabetes • Giant Cell Arteritis • Hematological Disorders • Ischemic stroke • Metabolic Disorders • Thrombosis